Sacubitril-valsartan led to a greater reduction of natriuretic peptides, less worsening renal function, but a higher rate of hypotension compared with valsartan in PARAGLIDE-HF.
A new device called bioadaptable, as opposed to bioabsorbable, was noninferior to a widely used drug eluting stent, and associated with several vessel functional improvements, in the BIOADAPTER trial.
After taking norethindrone acetate for 1 week every 4 weeks, 80% of participants reported satisfactory bleeding patterns with etonogestrel implants in a new study.
Stroke care is rife with inequities, a new AHA statement says, and fixing them will require more research into issues such as structural racism and other upstream social factors.